US 10040858
Anti-CSF1R antibodies for treating PVNS
granted A61KA61K2039/505A61K2039/545
Quick answer
US patent 10040858 (Anti-CSF1R antibodies for treating PVNS) held by Five Prime Therapeutics, Inc. expires Mon Aug 02 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Five Prime Therapeutics, Inc.
- Grant date
- Tue Aug 07 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 02 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 56
- CPC classes
- A61K, A61K2039/505, A61K2039/545, A61P, A61P19/02